Abstract

There is a paucity of data on the pulmonary immune-compartment interferon gamma (IFNγ) response to M. tuberculosis, particularly in settings of high tuberculosis (TB) prevalence and in HIV-coinfected individuals. This data is necessary to understand the diagnostic potential of commercially available interferon gamma release assays (IGRAs) in both the pulmonary immune-compartment and peripheral blood. We used intracellular cytokine staining by flow cytometry to assess the IFNγ response to purified protein derivative (PPD) and early secretory antigen 6 (ESAT6) in induced sputa (ISp) and blood samples from HIV-infected, smear-negative, TB suspects. We found that individuals with active TB disease produced significantly less IFNγ in response to PPD in their induced sputa samples than individuals with non-active TB (control group). This difference was not reflected in the peripheral blood, even within the CD27− CD4+ memory T lymphocyte population. These findings suggest that progression to active TB disease may be associated with the loss of IFNγ secretion at the site of primary infection. Our findings highlight the importance of studying pulmonary immune-compartment M. tuberculosis specific responses to elucidate IFNγ secretion across the spectrum of TB disease.

Highlights

  • TB remains one of the great killers despite adequate chemotherapeutic agents and a vaccine

  • The T-SPOT.TB and QuantiFERON-TB (QFN-TB) assays are commercially available enzyme-linked immunosorbent spot (ELISpot) and enzyme linked immunosorbent assays (ELISAs) that detect IFNγ released by M. tuberculosis antigen-specific cells

  • We investigated IFNγ responses to M. tuberculosis antigens in the pulmonary immunecompartment and peripheral blood of human immunodeficiency virus (HIV)-infected individuals suspected of having active TB, with initial sputum smears negative for acid fast bacilli (AFB)

Read more

Summary

Introduction

TB remains one of the great killers despite adequate chemotherapeutic agents and a vaccine. The T-SPOT.TB and QuantiFERON-TB (QFN-TB) assays are commercially available enzyme-linked immunosorbent spot (ELISpot) and enzyme linked immunosorbent assays (ELISAs) that detect IFNγ released by M. tuberculosis antigen-specific cells. These assays are the in vitro alternative to the widely used tuberculin skin test (TST) and offer higher M. tuberculosis specificity [5]. These IFNγ release assays (IGRAs) have shown limited use in high prevalent settings, as they are unable to differentiate between active and latent TB. Better characterisation of M. tuberculosis antigen-specific IFNγ responses may improve understanding of the complex immune response in TB and interpretation of IGRAs

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call